Table 3.

Ingestive and exploratory behaviors following administration of selective monoamine antagonists into vmPFC

	Food intake (g)	Mean eat bout duration (s)	Water intake (ml)	Mean drink bout duration (s)	Locomotor counts	Rearing counts
Muscimol-induced inactivation
0	5.2 ± 0.38	25.53 ± 1.98	4.1 ± 0.55	18.46 ± 3.97	51.57 ± 5.35	64.57 ± 8.96
75	5.3 ± 0.25	52.69 ± 3.79**	5.1 ± 0.57	16.12 ± 1.33	38.86 ± 5.93*	42.57
SCH23390
0	6.1 ± 0.64	60.4 ± 10.56	4.9 ± 0.61	27.2 ± 4.68	24.4 ± 3.93	51.0 ± 8.09
1	6.8 ± 0.51	58.8 ± 9.68	4.4 ± 0.85	25.6 ± 5.11	17.5 ± 2.73	36.6 ± 6.02
2	5.4 ± 0.58	64.1 ± 9.52	4.7 ± 0.60	24.6 ± 3.19	18.9 ± 2.42	37.8 ± 4.44
Raclopride
0	4.4 ± 0.48	48.3 ± 8.20	4.2 ± 1.0	19.4 ± 2.80	26.4 ± 5.15	53.0 ± 12.79
1	5.1 ± 0.43	47.1 ± 10.41	3.9 ± 0.90	22.6 ± 4.25	26.6 ± 3.88	65.7 ± 12.49
2	5.7 ± 0.45**	59.4 ± 12.97	3.8 ± 0.47	23.6 ± 3.95	21.7 ± 5.28	50.9 ± 10.43
WAY100635
0	6.2 ± 0.91	52.5 ± 9.57	7.0 ± 0.35	38.9 ± 11.37	24.8 ± 4.37	42.8 ± 5.74
2	5.6 ± 0.50	53.0 ± 8.06	5.1 ± 0.83	24.6 ± 4.40	26.8 ± 5.84	56.0 ± 15.64
MDL11939
0	4.4 ± 0.62	45.6 ± 14.61	2.6 ± 0.58	18.9 ± 3.04	25.9 ± 3.91	57.5 ± 10.34
0.15	5.8 ± 0.55*	68.1 ± 12.57*	3.5 ± 0.67	26.7 ± 7.16	19.1 ± 2.44	35.4 ± 6.24*
0.45	5.5 ± 0.40	50.2 ± 10.08	4.5 ± 0.46**	24.7 ± 2.94	26.0 ± 2.15	53.5 ± 5.51
Prazosin
0	4.6 ± 0.42	50.5 ± 9.81	4.6 ± 0.75	26.0 ± 3.97	30.8 ± 4.61	45.3 ± 6.88
0.25	4.4 ± 0.48	56.0 ± 12.61	4.8 ± 0.25	26.3 ± 3.88	28.8 ± 3.35	41.8 ± 10.68
B1 and B2 mixture
0	5.0 ± 0.29	52.0 ± 10.46	4.4 ± 0.63	20.8 ± 3.86	30.8 ± 2.75	62.3 ± 11.39
1/1	4.6 ± 0.29	53.8 ± 7.81	3.1 ± 0.63	15.4 ± 1.90	25.0 ± 3.34**	50.3 ± 8.38

Values represent mean ± SEM.

*p < 0.05,

**p < 0.01, compared with vehicle. All drug doses are in units of micrograms per 0.5 μl, except for muscimol dose, which is in units of nanograms per 0.5 μl.